IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation

Phase 1 Completed 18 enrolled Massachusetts General Hospital Agios Pharmaceuticals, Inc. · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This research study is studying a drug as a possible treatment for IDH1-mutant myeloid neoplasms. -The drug involved in this study is ivosidenib (AG-120)

Timeline

Start: 2019-01-16
Primary completion: 2022-05-22
Completion: 2023-06-06

Publications

Shallis RM, Podoltsev NA. Maintenance therapy for acute myeloid leukemia: sustaining the pursuit for sustained remission. Curr Opin Hematol. 2021 Mar 1;28(2):110-121. doi: 10.1097/MOH.0000000000000637.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ivosidenib	Small molecule	250 mg	Oral
Subject	Ivosidenib	Small molecule	500 mg	Oral

IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation

Summary

Timeline

Publications

Drugs

Indications